Pyxis Oncology
PYXS · Nasdaq · United States
Share price · PYXS
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when PYXS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 30 Sep 2026-19.7%
- 11 Aug 2026-26.1%
Nothing announced by PYXS that day or the session before.
- 6 Aug 2026+19.8%
Nothing announced by PYXS that day or the session before.
- 7 Jul 2026+24.8%
Nothing announced by PYXS that day or the session before.
- 26 Jun 2026+24.2%
Nothing announced by PYXS that day or the session before.
- 26 May 2026-16.8%
Nothing announced by PYXS that day or the session before.
- 14 May 2026-15.6%
- 8 May 2026+21.2%
- 6 May 2026+25.7%
Nothing announced by PYXS that day or the session before.
- 24 Apr 2026+11.1%
Nothing announced by PYXS that day or the session before.
Share of unusual movement by asset
For each asset, the share of PYXS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
MW02No recent activity | Phase 2/3 | VEGF-AMonoclonal antibody | Age-Related Macular Degeneration |
| Phase 1/2 | ED-B domain of fibronectinAntibody–drug conjugate | Solid Tumors |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
December 2027 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $17M | $3.9M+ $52M short-term inv. | $20M-$16M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $16M | $19M+ $14M short-term inv. | $25M-$18M operating cash flow | report ↗ |
| 2026-Q1 | — | $20M | $5.8M+ $35M short-term inv. | $23M-$26M operating cash flow | report ↗ |
| 2025-Q3 | — | $18M | $8.9M+ $67M short-term inv. | $22M-$13M operating cash flow | report ↗ |
| 2025-Q2 | $2.8M | $17M | $11M+ $78M short-term inv. | $18M-$17M operating cash flow | report ↗ |
| 2025-Q1 | — | $17M | $13M+ $93M short-term inv. | $21M-$23M operating cash flow | report ↗ |
| 2024-Q3 | — | $18M | $12M+ $133M short-term inv. | $21M-$15M operating cash flow | report ↗ |
| 2024-Q2 | — | $14M | $25M+ $131M short-term inv. | $17M-$3.0M operating cash flow | report ↗ |
| 2024-Q1 | $16M | $13M | $28M+ $129M short-term inv. | $3.3M-$21M operating cash flow | report ↗ |
| 2023-Q3 | — | $15M | $15M+ $118M short-term inv. | $23M-$18M operating cash flow | report ↗ |
| 2023-Q2 | — | $11M | $26M+ $117M short-term inv. | $16M-$11M operating cash flow | report ↗ |
| 2023-Q1 | — | $12M | $53M+ $96M short-term inv. | $19M-$27M operating cash flow | report ↗ |
| 2022-Q3 | — | $19M | $199M | $28M-$21M operating cash flow | report ↗ |
| 2022-Q2 | — | $17M | $223M | $26M-$24M operating cash flow | report ↗ |
| 2022-Q1 | — | $20M | $247M | $31M-$28M operating cash flow | report ↗ |
| 2021-Q3 | — | $7.8M | $133M | $14M | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $14M | $74M | $15M+ $51M short-term inv. | $20M-$64M operating cash flow | report ↗ |
Pyxis Oncology reported FY2025 revenue of $13.86M, down 14.2% YoY from $16.15M, with R&D spend of $73.7M, up 25.4% YoY from $58.75M. Cash and equivalents stood at $15.42M, and the company reported a net loss of $79.6M for the year.
The company guided that current cash, cash equivalents, and short-term investments should fund operations into Q4 2026. Clinically, target enrollment was completed in the Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ recurrent/metastatic head and neck squamous cell carcinoma in Q1 2026, with updated monotherapy data expected mid-2026 and updated combination data with KEYTRUDA expected in 2H26. Preliminary data showed a 46% confirmed objective response rate and 92% disease control rate for MICVO monotherapy, and a 71% confirmed ORR and 100% DCR in combination. The company also obtained FDA alignment on a planned pivotal monotherapy study and announced Thomas Civik as Interim CEO.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $16M | $59M | $19M+ $107M short-term inv. | $19M-$58M operating cash flow | report ↗ |
| 2023-FY | — | $50M | $9.7M+ $110M short-term inv. | $18M-$71M operating cash flow | report ↗ |
| 2022-FY | — | $86M | $179M | $30M-$89M operating cash flow | report ↗ |
| 2021-FY | — | $51M | $275M | $19M-$35M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($0), 1 sale ($107K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-06 | HUMPHREY RACHEL · director | Award / grant (derivative) | 34,500 | — | — | Form 4 |
| 2026-10-01 | GordonMD Global Investments LP; GordonMD Long Biased Master Fund LP; GordonMD Long Biased GP LLC; Gordon Craig D · 10% owner; 10% owner; 10% owner; 10% owner | Open-market purchase (derivative) | 7,172,000 | — | — | Form 4 |
| 2026-10-01 | GordonMD Global Investments LP; GordonMD Long Biased Master Fund LP; GordonMD Long Biased GP LLC; Gordon Craig D · 10% owner; 10% owner; 10% owner; 10% owner | Open-market purchase | 5,517,000 | — | — | Form 4 |
| 2026-10-01 | GordonMD Global Investments LP; GordonMD Long Biased Master Fund LP; GordonMD Long Biased GP LLC; Gordon Craig D · 10% owner; 10% owner; 10% owner; 10% owner | Open-market purchase (derivative) | 7,546,766 | — | — | Form 4 |
| 2026-09-04 | Civik Thomas · director, CEO & Chairman of the Board | Award / grant (derivative) | 2,503,050 | — | — | Form 4 |
| 2026-08-20 | Dupont Jakob · director | Award / grant (derivative) | 46,000 | — | — | Form 4 |
| 2026-08-12 | Civik Thomas · director, Interim CEO | Award / grant (derivative) | 250,956 | — | — | Form 4 |
| 2026-06-30 | Dupont Jakob · director | Option exercise | 35,000 | $1.60 | $56K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 77 reporting institutions held 27.6M shares ($40.3M, 23.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Pfizer Inc | 7,032,770 | $9.2M |
| 2 | Laurion Capital Management LP | 4,997,333 | $7.3M |
| 3 | GordonMD Global Investments LP | 4,121,870 | $6.0M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 2,033,510 | $3.0M |
| 5 | Atle Fund Management AB | 197,036 | $1.6M |
| 6 | Palo Alto Investors LP | 1,010,510 | $1.5M |
| 7 | 683 Capital Management, LLC | 896,263 | $1.3M |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 888,680 | $1.3M |
| 9 | BlackRock, Inc. | 788,839 | $1.2M |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 598,121 | $874K |
| 11 | Longaeva Partners L.P. | 503,214 | $735K |
| 12 | JACOBS LEVY EQUITY MANAGEMENT, INC | 460,997 | $673K |
| 13 | MILLENNIUM MANAGEMENT LLC | 397,625 | $581K |
| 14 | MARSHALL WACE, LLP | 354,417 | $517K |
| 15 | Decheng Capital LLC | 326,810 | $477K |